Cited by 874DNA and Nucleic Acid ChemistryAdvanced biosensing and bioanalysis techniquesRNA Interference and Gene Delivery

Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer

Open access
Bates, Paula J., Laber, Damian A., Miller, Donald M., Thomas, Shelia D., Trent, John O.·2009·Experimental and Molecular Pathology

Abstract

Certain guanine-rich (G-rich) DNA and RNA molecules can associate intermolecularly or intramolecularly to form four stranded or "quadruplex" structures, which have unusual biophysical and biological properties. Several synthetic G-rich quadruplex-forming oligodeoxynucleotides have recently been investigated as therapeutic agents for various human diseases. We refer to these biologically active G-rich oligonucleotides as aptamers because their activities arise from binding to protein targets via shape-specific recognition (analogous to antibody-antigen binding). As therapeutic agents, the G-rich aptamers may have some advantages over monoclonal antibodies and other oligonucleotide-based approaches. For example, quadruplex oligonucleotides are non-immunogenic, heat stable and they have increased resistance to serum nucleases and enhanced cellular uptake compared to unstructured sequences. In this review, we describe the characteristics and activities of G-rich oligonucleotides. We also give a personal perspective on the discovery and development of AS1411, an antiproliferative G-rich phosphodiester oligonucleotide that is currently being tested as an anticancer agent in Phase II clinical trials. This molecule functions as an aptamer to nucleolin, a multifunctional protein that is highly expressed by cancer cells, both intracellularly and on the cell surface. Thus, the serendipitous discovery of the G-rich oligonucleotides also led to the identification of nucleolin as a new molecular target for cancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.yexmp.2009.01.004

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AS1411 aptamer specifically binds to nucleolin, which is highly expressed on nucleus and tumor cell membranes.

    “AS1411 aptamer is a 26-molecule DNA oligonucleotide accidentally discovered by Bates et al.253 It can specifically bind to nucleolin, which is highly expressed on the nucleus and on the surface of tumor cell membranes.254”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [253]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [119]Girvan AC 2006 Mechanistic studies of guanine-rich oligonucleotides (Doctoral Dissertation) University of Louisville Electronic Theses and Dissertations

Cited by

Sorted by citations

Authors
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O.
Affiliations
University of Louisville (US)
Corresponding author
Bates, Paula J.
Venue
Experimental and Molecular Pathology
Publisher
Elsevier BV
Published
2009-06
Volume
86
Issue
3
Pages
151-164
ISSN
0014-4800 (ISSN-L)
OpenAlex
W2041919391
Cited by
874
References
172
Citations by year
2026: 40 · 2025: 50 · 2024: 48 · 2023: 60 · 2022: 65 · 2021: 61 · 2020: 59 · 2019: 68 · 2018: 67 · 2017: 55 · 2016: 54 · 2015: 65 · 2014: 41 · 2013: 44 · 2012: 40
FWCI
2.39
Type
journal article
Language
en
Open access
Locations
  • Experimental and Molecular Pathology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA113735, R01CA122383, R21CA104230, R21CA091115)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
AS1411, G-rich oligonucleotides, G-quadruplex, aptamers, nucleolin, anticancer agents, phosphodiester oligonucleotides, cancer therapy
MeSH terms
Nucleolin, Animals, Antineoplastic Agents, Clinical Trials as Topic, Drug Screening Assays, Antitumor, Humans, Neoplasms, Oligodeoxyribonucleotides, Phosphoproteins, Molecular Structure, RNA-Binding Proteins, Cell Proliferation, Aptamers, Nucleotide, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review